Total Payments
$215,562
2024 Payments
$19,469
Companies
7
Transactions
187
Medicare Patients
527
Medicare Billing
$133,973
Payment Breakdown by Category
Research$213,834 (99.2%)
Consulting$1,000 (0.5%)
Food & Beverage$713.85 (0.3%)
Travel$14.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $213,834 | 174 | 99.2% |
| Consulting Fee | $1,000 | 1 | 0.5% |
| Food and Beverage | $713.85 | 10 | 0.3% |
| Travel and Lodging | $14.00 | 2 | 0.0% |
Payments by Type
Research
$213,834
174 transactions
General
$1,728
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk AS | $214,096 | 180 | $0 (2024) |
| EISAI INC. | $1,096 | 2 | $0 (2019) |
| Stryker Corporation | $144.43 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $119.71 | 1 | $0 (2023) |
| Chiesi USA, Inc. | $51.85 | 1 | $0 (2019) |
| Integra LifeSciences Corporation | $35.72 | 1 | $0 (2022) |
| Ceribell, Inc. | $18.20 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19,469 | 17 | Novo Nordisk AS ($19,325) |
| 2023 | $48,395 | 36 | Novo Nordisk AS ($48,275) |
| 2022 | $61,295 | 41 | Novo Nordisk AS ($61,259) |
| 2021 | $51,125 | 37 | Novo Nordisk AS ($51,125) |
| 2020 | $22,143 | 30 | Novo Nordisk AS ($22,125) |
| 2019 | $8,473 | 17 | Novo Nordisk AS ($8,325) |
| 2018 | $4,662 | 9 | Novo Nordisk AS ($3,662) |
All Payment Transactions
187 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/22/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,750.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 10/22/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,750.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 09/10/2024 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $350.00 | Research |
| Study: NN9535-4533 • Category: Diabetes | ||||||
| 08/13/2024 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $200.00 | Research |
| Study: NN9535-4533 • Category: Diabetes | ||||||
| 08/07/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,350.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 07/18/2024 | Stryker Corporation | ADHERUS AUTOSPRAY ET DURAL SEALANT (Device), UNIVERSAL NEURO 3, HYDROSET | Food and Beverage | In-kind items and services | $144.43 | General |
| Category: CRANIOMAXILLOFACIAL | ||||||
| 07/03/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $2,175.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 06/20/2024 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $200.00 | Research |
| Study: NN9535-4533 • Category: Diabetes | ||||||
| 05/23/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $2,050.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 05/23/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $825.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 04/04/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,400.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 02/29/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,775.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 02/21/2024 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $375.00 | Research |
| Study: NN9535-4533 • Category: Diabetes | ||||||
| 02/07/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $2,625.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 02/07/2024 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $475.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 01/19/2024 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $975.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 01/05/2024 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,050.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 12/08/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $725.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 11/28/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,325.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 11/07/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $700.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 10/19/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 10/19/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $300.00 | Research |
| Study: NN9535-4533 • Category: Diabetes | ||||||
| 10/10/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $1,150.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
| 10/06/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | Cash or cash equivalent | $2,675.00 | Research |
| Study: EX9924-4473 • Category: Diabetes | ||||||
| 09/12/2023 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $775.00 | Research |
| Study: NN9535-4321 • Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EX9536-4388 | Novo Nordisk AS | $89,075 | 46 |
| EX9924-4473 | Novo Nordisk AS | $83,884 | 57 |
| NN9535-4321 | Novo Nordisk AS | $35,100 | 47 |
| NN9535-4533 | Novo Nordisk AS | $2,225 | 8 |
| NN9536-4374 | Novo Nordisk AS | $1,400 | 4 |
| NN9536-4373 | Novo Nordisk AS | $1,025 | 5 |
| NN9536-4375 | Novo Nordisk AS | $375.00 | 1 |
| NN9536-4378 | Novo Nordisk AS | $375.00 | 3 |
| NN9536-4379 | Novo Nordisk AS | $250.00 | 2 |
| NN9536-4376 | Novo Nordisk AS | $125.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 106 | 145 | $88,582 | $22,497 |
| 2022 | 4 | 159 | 241 | $145,008 | $37,168 |
| 2021 | 4 | 153 | 283 | $166,307 | $42,449 |
| 2020 | 4 | 109 | 192 | $105,640 | $31,859 |
Total Patients
527
Total Services
861
Medicare Billing
$133,973
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 64 | 91 | $60,697 | $15,114 | 24.9% |
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2023 | 26 | 36 | $22,017 | $5,758 | 26.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 16 | 18 | $5,868 | $1,625 | 27.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 87 | 138 | $93,603 | $23,640 | 25.3% |
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2022 | 31 | 56 | $35,053 | $9,223 | 26.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 28 | $8,805 | $2,270 | 25.8% |
| 95718 | Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | Facility | 2022 | 16 | 19 | $7,547 | $2,035 | 27.0% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 70 | 156 | $107,172 | $27,410 | 25.6% |
| 95720 | Continuous measurement of brain wave activity with video (veeg), 12-26 hours, with health care professional analysis, interpretation and report | Facility | 2021 | 25 | 45 | $28,845 | $7,198 | 25.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 44 | 68 | $21,624 | $5,589 | 25.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 14 | 14 | $8,666 | $2,253 | 26.0% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 43 | 80 | $54,960 | $16,844 | 30.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 33 | 64 | $20,352 | $6,407 | 31.5% |
| 95720 | Continuous measurement of brain wave activity with video (veeg), 12-26 hours, with health care professional analysis, interpretation and report | Facility | 2020 | 14 | 28 | $17,948 | $4,769 | 26.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 19 | 20 | $12,380 | $3,840 | 31.0% |
About Dr. Keith Dombrowski, M.D
Dr. Keith Dombrowski, M.D is a Neurology healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2007. The National Provider Identifier (NPI) number assigned to this provider is 1548477490.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Keith Dombrowski, M.D has received a total of $215,562 in payments from pharmaceutical and medical device companies, with $19,469 received in 2024. These payments were reported across 187 transactions from 7 companies. The most common payment nature is "" ($213,834).
As a Medicare-enrolled provider, Dombrowski has provided services to 527 Medicare beneficiaries, totaling 861 services with total Medicare billing of $133,973. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurocritical Care
- Location Tampa, FL
- Active Since 05/17/2007
- Last Updated 04/28/2023
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1548477490
Products in Payments
- Wegovy (Drug) $70,175
- Rybelsus (Drug) $57,459
- Ozempic (Drug) $37,450
- RYBELSUS (Drug) $25,400
- Fycompa (Drug) $1,096
- ADHERUS AUTOSPRAY ET DURAL SEALANT (Device) $144.43
- CLEVIPREX (Drug) $51.85
- CODMAN CERTAS (Device) $35.72
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Tampa
Derrick Robertson, M.d, M.D
Neurology — Payments: $2.3M
Neurology $2.3M
Selim Benbadis, Md, MD
Neurology — Payments: $2.3M
Neurology $2.3M
Dr. Mark Cascione, M.d, M.D
Neurology — Payments: $1.9M
Neurology $1.9M
Robert Hauser, Md, MD
Neurology — Payments: $1.5M
Neurology $1.5M
David Rose, M.d, M.D
Neurology — Payments: $1.5M
Neurology $1.5M
Dr. Katherine Standley, Do, DO
Neurology — Payments: $1.3M
Neurology $1.3M